Aquestive Therapeutics, Inc. | Business Contracts

Executive Employment Agreement between the Company and Daniel Barber, effective on July 15, 2022 (Filed With SEC on August 2, 2022)

Form of Securities Purchase Agreement dated June 6, 2022, by and among Aquestive Therapeutics, Inc. and the purchasers (Filed With SEC on June 8, 2022)

Placement Agency Agreement dated June 6, 2022, between Aquestive Therapeutics, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on June 8, 2022)

License, Development and Supply Agreement, dated as of March 2022, by and between Aquestive Therapeutics, Inc. and Haisco Pharmaceutical Group Co., Ltd (Filed With SEC on May 4, 2022)

Consent Fee Letter, dated October 7, 2021, among Aquestive Therapeutics, Inc. and the Noteholder parties thereto (Filed With SEC on October 8, 2021)

Form of Common Stock Warrant (Filed With SEC on June 8, 2022)

Form of Pre-Funded Warrant (Filed With SEC on June 8, 2022)

Amendment No. 2 to the Purchase Agreement, dated as of May 13, 2022, by and among the Aquestive Therapeutics, Inc. and the Purchasers signatory thereto (Filed With SEC on May 17, 2022)

Fifth Supplemental Indenture, dated May 13, 2022, among Aquestive Therapeutics, Inc., as Issuer, any Guarantor that becomes party thereto and U.S. Bank Trust Company, National... (Filed With SEC on May 17, 2022)

Separation Agreement, dated May 17, 2022, between Aquestive Therapeutics, Inc. and Keith J. Kendall (Filed With SEC on May 17, 2022)

Registration Rights Agreement, dated as of April 12, 2022, by and between the Company and Lincoln Park (Filed With SEC on April 13, 2022)

Purchase Agreement, dated as of April 12, 2022, by and between the Company and Lincoln Park (Filed With SEC on April 13, 2022)

First Amendment to Executive Employment Agreement, dated as of June 30, 2021, by and between Aquestive Therapeutics, Inc. and Keith J. Kendall (Filed With SEC on March 8, 2022)

First Amendment to Executive Employment Agreement, dated as of June 30, 2021, by and between Aquestive Therapeutics, Inc. and Alexander Mark Schobel (Filed With SEC on March 8, 2022)

Fourth Supplemental Indenture, dated October 7, 2021, among Aquestive Therapeutics, Inc., as Issuer, any Guarantor that becomes party thereto and U.S. Bank, National Association,... (Filed With SEC on October 8, 2021)

Waiver Agreement dated as of September 30, 2021, among Aquestive Therapeutics, Inc., at the Noteholder party thereto (Filed With SEC on October 6, 2021)

Third Supplemental Indenture, dated August 6, 2021, among Aquestive Therapeutics, Inc., as Issuer, any Guarantor that becomes party thereto and U.S. Bank, National Association, as... (Filed With SEC on August 9, 2021)

Letter Agreement between the Company and A. Ernest Toth, Jr. , effective on June 15, 2021 (Filed With SEC on August 3, 2021)

Third Amendment to License Agreement by and between Aquestive Therapeutics, Inc. and Sunovion Pharmaceuticals Inc. (formerly, Cynapsus Therapeutics, Inc.) (Filed With SEC on July 30, 2021)

Amendment No. 1 to the Equity Distribution Agreement, dated March 26, 2021, by and between Aquestive Therapeutics, Inc. and Piper Sandler & Co (Filed With SEC on March 26, 2021)

Purchase and Sale Agreement, dated as of November 3, 2020, by and between Aquestive Therapeutics, Inc. and MAM Pangolin Royalty, LLC (Filed With SEC on March 9, 2021)

Second Amendment to License Agreement, by and between Aquestive Therapeutics, Inc. and Sunovion Pharmaceuticals, Inc., dated as of October 23, 2020 (Filed With SEC on March 9, 2021)

Separation Agreement, dated as of December 16, 2020, by and between Aquestive Therapeutics, Inc. and John T. Maxwell (Filed With SEC on March 9, 2021)

Form of 2020 Purchase Agreement in connection with the 2020 issuance of 12.5% Senior Secured Notes (Filed With SEC on March 9, 2021)

Second Supplemental Indenture dated November 20, 2020, among Aquestive Therapeutics, Inc., as Issuer, any Guarantor that becomes party thereto and U.S. Bank National Association,... (Filed With SEC on March 9, 2021)

First Supplemental Indenture dated November 3, 2020, among Aquestive Therapeutics, Inc., as Issuer, any Guarantor that becomes party thereto and U.S. Bank National Association, as... (Filed With SEC on March 9, 2021)

Paycheck Protection Program Promissory Note dated April 17, 2020, between Aquestive Therapeutics, Inc., as Borrower, and Frost Bank, as Lender (Filed With SEC on April 20, 2020)

First Amendment to License Agreement, effective as of March 16, 2020, by and between Aquestive Therapeutics, Inc. and Sunovion Pharmaceuticals Inc. (formerly, Cynapsus... (Filed With SEC on March 20, 2020)

Aquestive Therapeutics, Inc. Employee Stock Purchase Plan as Amended (Filed With SEC on March 11, 2020)

Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 11, 2020)

Underwriting Agreement, dated December 12, 2019, by and between Aquestive Therapeutics, Inc. and BMO Capital Markets Corp., as representative of the several underwriters named... (Filed With SEC on December 16, 2019)

Form of Purchase Agreement (Filed With SEC on July 16, 2019)

Form of Warrant (Filed With SEC on July 16, 2019)

Collateral Agreement dated as of July 15, 2019 among Aquestive Therapeutics, Inc., as Issuer, the Other Grantors from time to time party thereto, U.S. Bank National Association,... (Filed With SEC on July 16, 2019)

Indenture Dated as of July 15, 2019, among Aquestive Therapeutics, Inc., as Issuer, any Guarantor that becomes party thereto and U.S. Bank National Association, as Trustee and... (Filed With SEC on July 16, 2019)

Aquestive Therapeutics, Inc. Employee Stock Purchase Plan (Filed With SEC on June 18, 2019)

Aquestive Therapeutics, Inc. (36)